Harmony Biosciences Holdings, Inc., founded on July 25, 2017, is a commercial-stage pharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with rare neurological diseases with unmet medical needs. The company's product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action, or MOA, specifically designed to enhance histamine signaling in the brain by binding to H3 receptors.
